Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
In a recent transaction, Ranmali Bopitiya, the Executive Vice President & Chief Legal Officer of Oscar Health, Inc. (NYSE:OSCR), sold a significant number of shares in the company. According to the latest filings, Bopitiya sold 36,175 shares on September 3rd at an average price of $17.99, and an additional 33,978 shares on September 4th at prices ranging from $17.46 to $17.85. The total value of the shares sold amounted to over $1.2 million.
The sales were conducted under a pre-arranged 10b5-1 trading plan, which allows company insiders to sell shares at predetermined times to avoid accusations of insider trading. This plan had been established prior to February 27, 2023, with the purpose of covering tax withholding obligations related to the vesting of equity awards.
Oscar Health, a provider of health insurance products and services, has seen its stock undergo various transactions by its executives, which are closely watched by investors for insights into the company's performance and the confidence level of its top management.
Bopitiya's transactions come as part of the regular vesting and subsequent sale of shares granted as equity awards. Before these sales, Bopitiya acquired shares through the vesting of restricted stock units (RSUs). The RSUs represent a contingent right to receive Oscar Health's Class A common stock and are part of a compensation strategy to align the interests of the company's executives with those of the shareholders.
The filing did not disclose any purchase transactions for the period, indicating that the focus was on the disposition of shares. Following these transactions, Bopitiya continues to hold a substantial number of shares in the company, reflecting ongoing involvement in the company's growth and performance.
Investors and market analysts often review the trading activities of company insiders for signals about the company's prospects and strategic direction. The sales by Oscar Health's EVP & Chief Legal Officer will likely be interpreted within the broader context of the company's operational performance and stock market trends.
For more detailed information regarding the transactions, Oscar Health investors and the Securities and Exchange Commission staff can request full transaction details from the reporting person.
In other recent news, Oscar Health has reported robust Q2 results, with total revenue reaching $2.2 billion, marking a 46% year-over-year increase. The company's medical loss ratio saw improvement, and adjusted EBITDA experienced significant growth. These strong results have led Oscar Health to revise its full-year 2024 revenue and adjusted EBITDA guidance upwards. The revenue guidance for 2024 has been increased by 8.4% at the midpoint, and the adjusted EBITDA guidance has seen a 23.3% hike.
Following these developments, Piper Sandler has raised its price target for Oscar Health from $25.00 to $28.00, maintaining an Overweight rating on the stock. This decision reflects the firm's confidence in Oscar Health's financial trajectory for the upcoming year.
Despite expecting an increase in the medical loss ratio for the full year, Oscar Health is optimistic about achieving total company adjusted EBITDA profitability this year. The company's focus on expanding its market presence and diversifying growth through the Individual Coverage Health Reimbursement Arrangement (ICRA) business is central to its long-term financial goals. These recent developments underscore Oscar Health's financial strength and strategic initiatives aimed at long-term growth.
InvestingPro Insights
Oscar Health, Inc. (NYSE:OSCR), a major player in the health insurance sector, has been a subject of interest for investors trying to gauge the company's financial health and future prospects. With the recent insider transactions, it's essential to look at the company's performance through the lens of InvestingPro metrics and tips.
As of the last twelve months leading up to Q2 2024, Oscar Health has demonstrated a robust revenue growth of 45.16%, with its revenue reaching approximately $7.23 billion. This significant increase is reflected in a quarterly growth rate of 45.86%, signaling strong sales and business expansion. Despite this, the company's gross profit margin stands at 22.12%, which, according to an InvestingPro Tip, indicates that Oscar Health suffers from weak gross profit margins compared to some of its industry peers.
The company's P/E ratio is currently high at 221.65, suggesting that Oscar Health is trading at a premium relative to its earnings. This is further supported by an InvestingPro Tip that highlights the company's high earnings multiple and high P/E ratio relative to near-term earnings growth. It's important to note that this could be a point of concern for value-focused investors, as the stock might be considered overvalued in terms of its earnings.
Despite the high valuation metrics, analysts following Oscar Health have a positive outlook, with predictions that the company will be profitable this year. This aligns with the company's recent profitability over the last twelve months, as evidenced by a basic and diluted EPS (Continuing Operations) of $0.08. Additionally, the stock has experienced a significant price uptick of 25.38% over the last six months, with a year-to-date return of 90.6%, which could indicate investor optimism about the company's trajectory.
Investors interested in Oscar Health's stock performance and future earnings potential can find additional insights, with a total of 11 InvestingPro Tips available on the platform, offering a comprehensive analysis of the company's financial health and stock valuation. To explore these insights, visit https://www.investing.com/pro/OSCR.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.